NAWIN C. MISHRA, PhD, is an Emeritus Professor of Molecular Genetics and Genomics in the Department of Biological Sciences at the University of South Carolina. Dr. Mishra was the member of Biology faculty 1973-2006 first as Associate Professor and later as Full Professor and Distinguished Professor He was also involved with Dept of Microbiology at the USC medical school first as Ad-hoc Chair of the dept during its formation year and later as adjunct faculty .
He received his B.Sc ( Hons) and M.Sc. from Science college , Patna University and his Ph. D from the McMaster University , Hamilton , Ont. Canada in 1967. He was a merit scholar at the University of Patna and a Fellow of the Government of Ontario at the McMaster University.
He received his Postdoctoral training 1967-1973 with the late Nobel laureate Professor E. L. Tatum at the Rockefeller University in New York; there he initiated the landmark gene transfer experiments in fungi With Professor Tatum at the Rockefeller University (1967-1973). At the Rockefeller University he was the recipient of Fellowship for Medical Research of the Jane Coffin Child Fund of the Yale University.
Nawin Mishra(Research Area)
Molecular Genetics, Fungal Genetics, Molecular Biology, Genetics and Nucleic Acids,
Michael D. West, Ph.D. has served as our Chief Executive Officer since 2007, and has served on the Board of Directors since 2002. Dr. West also serves as a Director of BioTime company Asterias Biotherapeutics (NYSE MKT: AST). From 1998 to 2007, Dr. West served as CEO, President, and Chief Scientific Officer of Advanced Cell Technology, Inc. (now Ocata Therapeutics, Nasdaq: OCAT), a company engaged in developing human stem cell technology for use in regenerative medicine.
In 1990 Dr. West founded Geron Corporation (Nasdaq: GERN) of Menlo Park, California, which may have been the first regenerative medicine company. He secured investment in Geron from Kleiner Perkins Caufield Byers, Venrock and other venture capital firms, and for the companyâ€™s Scientific and Clinical Advisory Board he recruited Nobel Laureates Drs. Carol Greider and James Watson, as well as Leonord Hayflick and others. He also created the research consortium with Drs. James Thomson and John Gearhart that led to the first isolation of human embryonic stem cells.
Dr. West received a B.S. Degree from Rensselaer Polytechnic Institute in 1976, an M.S. Degree in Biology from Andrews University in 1982, and a Ph.D. from Baylor College of Medicine in 1989 concentrating on the biology of cellular aging.
Hong Lin received his PhD in Computer Science in 1997 at the University of Science and Technology of China. Hong Lin was a postdoctoral research associate at Purdue University; an assistant research officer at the National Research Council, Canada, and a software engineer at Nokia, Inc. Dr. Lin is currently a professor in computer science and an assistant chair at the Department of Computer Science and Engineering Technology. His research interests include human-centered computing, cognitive intelligence, data analytics, and parallel/distributed computing. He is the supervisor of the Grid Computing Lab at UHD. He is also a senior member of the Association for Computing Machinery (ACM).
Hong Lin(Research Area)
virtual 3D images of natural sceneries, Brain State Modeling, healthcare applications, psychological and mental problems, Stem Cells, Regenerative Medicine
Experienced Staff Scientist with a demonstrated history of working in the research industry. Skilled in CRISPR/Cas9, Mouse Models, Stem Cells, Tissue Culture, and Molecular Biology. Strong research professional with a Doctor of Philosophy (PhD) focused in Biomedical Sciences, from The University of Sheffield.
Professor of the Center for Personalized Medicine - Sechenov Medical University (Moscow);
Head of the General Pathology Department - Veltischev Pediatric Institute of Pirogov Medical University (Moscow);
Among main scientific achievements: the identification of the stimulating effect of low-intensity laser on the regeneration of germ cells, the description of pathological complex changes in skeletal muscle tissue in mitochondrial diseases in children, the development of methodological approaches to the laboratory diagnostics of primary and secondary disorders of cellular energy metabolism, the description of the phenomenon of "energy deficient diathesis", development of the hypothesis of adaptive and compensatory proliferative potential of mitochondria in humans. Important point of his activity now - an organization of investigations in different aspects of pediatric pathology (mitochondrial diseases, other inherited metabolic diseases, neuromuscular diseases, and the like) with use of chromatography, mass-spectroscopy, molecular-genetic, immunohistochemical studies, electron microscopy and other.
Dr. Tapan Bera received his M.S. and PhD in Biochemistry from the Calcutta University, India. He completed his postdoctoral research training in the Cancer Research Laboratory, UC Berkeley and in the Laboratory of Molecular Biology, National Cancer Institute. Currently he held the Associate Scientist position at the National Cancer Institute, NIH, USA. His research objectives are focused mainly on to understand the molecular basis of cancer by identifying the genes involved in this process and translate that information to possible targeted therapy of cancer. Dr Bera has discovered several very interesting and important genes whose expression is restricted to normal prostate and prostate cancer and are now being developed as therapeutic targets for the treatment of prostate cancer. Dr Bera is author/co-author in more than 65 papers published in peer-reviewed journals.
Tapan K Bera(Research Area)
Molecular Biology,Genes Studies,Cancer biology and Immunotherapy
A seasoned life sciences executive with experience in biologics, small molecules and medical devices, Valentin is a medical doctor who has established and led companies from inception to major value inflection, including taking public one of the companies that he founded.
During his career, Valentin has climbed all the steps of the biopharmaceutical career, starting as a research scientist and up to the President and CEO level. Implementing lessons learned at each stage and combining them with his medical education, he has led the development of several technologies from scientific concept to advanced human clinical trials. As Senior VP of Development at one of the first cell therapy companies in the world, and then as CEO of a stem cell company, he has been intimately involved in the development of cell therapy products, their manufacturing and analytical processes, while working hand in hand with the FDA and Health Canada. In addition to cell therapies, Valentin has also worked in drug and medical device development. He has managed clinical trials, has developed clinical and pre-clinical protocols and many other regulatory documents.
Valentin Fulga(Research Area)
Stem cells, Stem Cells Therapy, Advanced Human Clinical Trials
Yukihito Ishizaka graduated Tohoku University, School of Medicine in Japan, and has obtained the Doctor of Medical Science from Jichi Medical School. He is the director of Department of Intractable Diseases and the Vice Director General of Research Institute of NCGM. His scientific interest is genomic instability during carcinogenesis, and initiated the current project just when he started HIV-1 research.
Yukito Ishizaka (Research Area)
DNA damage in infection with HIV-1, Development of novel cell transformation, autoantibodies in collagen disease patient's pathogenesis, Regenerative Medicine, Stem Cells.
Jiamin Teng is a Professor in the Department of Pathology and Translational Pathobiology, Louisiana State University Health Sciences Center in Shreveport
(LSUHSC), USA. She completed Masterâ€™s Degree from Tongji Medical University in Wuhan, China and her PhD in Nihon University School of Medicine in
Tokyo, Japan. Her research focuses on glomerulosclerosis of kidney damage and the stem cell regeneration, which can be translated to diabetic nephropathy
due to similarities in pathogentic mechanisms involved. Her laboratory has developed unique experimental models such as live cell micromanipulation model, 6
dimensional live cell observation models, ex vivo kidney perfusion model and in vivo model for the kidney glomeruli damage and reparation. These models have
well served for the purpose of kidney pathogenic and regeneration.
Founder & Chief Scientist, Hapto Biotech Israel, 2000-2009(A subdivision of Forticell Bioscience NY from 2007.
Head of Laboratory of Biotechnology and Radiobiology, in the Cancer Research Laboratories
Sharett Institute of Oncology, Hadassah Ein Kerem Hospital
Raphael Gorodetsky(Research Area)
Fibrin based technologies for adult stem cells isolation expansion and implantation,Progenitor cell based implants for tissue regeneration,Development of bead-based anticancer immunotherapy.
Luca Gentile graduated in Developmental Biology in 2000 and received his PhD in Bioengineering and Bioinformatics at the University of Pavia (ITA). In 2003, he
was invited to the Center for Animal Transgenesis and Germ Cell Research (Kenneth Square, PA, USA) for studying reprogramming in single reconstructed mouse
embryos. In 2004, he joined the Max Planck Institute for Molecular Biomedicine (MÃ¼nster, GER), working on the onset of cellular reprogramming. In 2010, he was
appointed Head of the Planarian Stem Cell Laboratory (MÃ¼nster, GER), working on the conserved mechanisms of pluripotency. In the same year, he organized
the first International Meeting on Planarian Biology, which in 2018 reaches its 4th edition (Madison, WI, USA). Since March 2015, he leads the Pluripotency &
Regeneration Group at the Fraunhofer Institute for Biomedical Engineering (Sulzbach, GER). His subjects of investigation are the derivation of human cardiac
organoids and the functional characterization of stem cell subpopulations in planarian S. mediterranea.
Dr. Martin Morad is an internationally recognized scientist in the field of cardiac electrophysiology and calcium signaling, specifically in the area of calcium-binding protein.The cardiac muscle is a complex system composed of 40,000 proteins. These proteins dictate how the heart contracts and how fast. They also control how heart muscle grows and regenerates. Calcium acts as a signaling mechanism in the function of these proteins. Dr. Morad seeks to discover what causes these calcium-signaling mechanisms to stop working properly, which can result in congestive heart failure. Understanding this process could lead to new therapeutic approaches to treat congestive heart failure and other conditions.
Additionally, Dr. Moradâ€™s research could lead to the worldâ€™s first tissue-derived human heart pacemaker. A biological pacemaker derived from genetically engineered cells has great commercial viability as a replacement for current pacemaker technology made from artificial materials.
Martin Morad(Research Area)
mechanisms in cardiac muscle, calcium signaling, cardiac electrophysiology, Stem Cells, Regenerative Medicine
Mohamed H. Doweidar is a full associate professor at the Mechanical Engineering Department, University of Zaragoza, Spain. Besides, he is a member of the Biomedical Research Networking center in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), the AragÃ³n Institute of Engineering Research (I3A) and the European Society of Biomechanics. He received his Ph.D. degree in Computational Fluid Mechanics (2005) beside to a Diploma in Advanced Studies in Computational Fluid Mechanics (2004) from Zaragoza University, Spain; M.Sc. in Engineering Mathematics (2001) from Ain Shams University, Egypt; B.Sc. in Statistical and Computer Science (1997) from Mansoura University, Egypt; B.Sc. in industrial engineering (1993) from Benha Higher Institute of Technology, Egypt. Dr. Doweidar has participated in many national and international investigation projects. In addition, he is author and coauthor of many books and articles in national and international journals. His investigation interests include Computational Biomechanics, Cell Simulation, Hyperelastic Materials, Large Deformations, Finite Element Method, Natural Element Method, Computational Fluid Dynamics, Error Estimation and Adaptively.
Mohamed Hamdy Doweidar(Research Area)
Computational Biomechanics, Cell Simulation, Hyperelastic Materials, Stem Cells, Regenerative Medicine, Large Deformations, Finite Element Method, Natural Element Method, Computational Fluid Dynamics
Artemis Stamboulis has research interests in the microstructural characterisation of materials for biomedical applications. She has published over 40 research papers in international scientific journals. Artemis has an active research group and has supervised more than 30 postgraduate students.
Artemis teaches at both undergraduate and postgraduate level (MRes in Biomaterials) and is interested in Education Research and particularly in Threshold Concepts in Engineering, a research activity that is funded by the Royal Academy of Engineering.
Artemis Stamboulis(Research Area)
orthopaedic applications, ceramic nanocomposites for medical applications, Nanostructures for biomedical applications, Tissue Engineering Module Coordinator, Stem Cells, Regenerative Medicine
Stuart Lipton, MD, PhD, is a board-certified neurologist who specializes in neurodegenerative diseases. A neuroscientist and world-renowned expert in dementia, Dr. Lipton is best known for developing the FDA-approved memantine (NamendaÂ®, NamendaXRÂ®, NamzaricÂ®), the first drug in a novel class of medications used to treat moderate-to-severe Alzheimerâ€™s disease.
In addition to his clinical practice in general neurology, Dr. Lipton is a prolific researcher whose studies have led to the development of the first neuroprotective drugs to combat various neurodegenerative diseases, vascular diseases of the brain, and neurodevelopment disorders such as autism. He is an adjunct professor at UC San Diego School of Medicineâ€™s Department of Neurosciences and professor and co-director of the Neuroscience Translational Center at The Scripps Research Institute in La Jolla. Dr. Lipton also holds the Hannah and Eugene Step Chair in neurodegenerative disease.
As a translational research scientist, Dr. Lipton applies findings in basic research to produce new drugs and treatment options for people to improve their health and well-being. His areas of expertise include pharmacology and stem cell biology.
Dr. Lipton is extensively published. He has co-authored over 500 articles, books and papers. His work, which has appeared in journals such as Science, Nature, Cell, The New England Journal of Medicine, JAMA and The Lancet, among others, has been cited over 64,000 times.
Before relocating to San Diego, Dr. Lipton served on the faculty at Harvard Medical School for 25 years.
Dr. Lipton completed his neurology residency at Harvard University where he also performed his PhD thesis research in biochemistry and biophysics. As a postdoctoral fellow in the Department of Neurobiology at Harvard University, Dr. Lipton studied under Torsten N. Wiesel, MD, when Weisel won the Nobel Prize in 1981. Dr. Lipton earned his medical degree from the University of Pennsylvania School of Medicine. He is board certified in neurology.
He is an elected fellow of the American Association for the Advancement of Science and the American Neurological Association.
In 2004, for his work on developing the drug memantine, Dr. Lipton was the recipient of the Ernst Jung Prize for Medicine, considered one of the top five or six medical prizes worldwide.
Stuart A. Lipton(Research Area)
intracellular signaling pathways in nerve cells, the development of the first glutamate receptor/channel antagonist drug (Memantine), neurodegenerative and vascular diseases of the brain, Stem Cells, Regenerative Medicine
Jehan El Sharnouby has completed her PhD from Tanta University and Post-doctoral studies from Tanta University, Faculty of Medicine. She is the Director of Hematology and Bone Marrow Biopsy Unit. She has published more than 25 papers in reputed journals and has been serving as an Editorial Board Member of
I received for the obtained results an International Award of the U.S. Stanley Foundation. The results of my research on schizophrenia have been considered the first direct evidence of virus infection in the central nervous system in schizophrenia [Journal of Microbiology Review, 1995] obtained in the studies of brains of fetuses of schizophrenic mothers.